GoodRx, the prescription drugs marketplace, has submitted a formal filing to go public with the U.S. Securities and Exchanges Commission. Investment banks Morgan Stanley, Goldman Sachs, J.P. Morgan, and Barclays are acting as lead underwriters for the company’s public listing. GoodRx’s S-1 filing indicates the company recorded $388 million in revenues last year and a net income of $66 million. GoodRx being profitable stands out in a slew of technology companies currently looking to go public, of which many aren’t profitable.

GoodRx has been profitable for four years straight, as indicated by its S-1 filing. In 2018, the company recorded $249.5 million in revenue and $43.7 million in net income. For the first six months of this year, GoodRx reports $256.7 million in revenue and a net income of $54.7 million.

GoodRx currently makes do with just 338 employees, the majority of whom are based in its headquarters in the city of Santa Monica.